SPTLC1 Antibody

What is the optimal protocol for using SPTLC1 antibodies in Western blotting?

Western blotting with SPTLC1 antibodies requires careful optimization to ensure reliable and reproducible results. The following protocol has been validated across multiple experimental systems:

Sample Preparation:

• Extract proteins using RIPA buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS) with protease inhibitors and phosphatase inhibitors (especially 0.1 μM sodium orthovanadate) .

• Homogenize tissue samples with mechanical disruption and clarify lysates by centrifugation at 14,000 × g for 15 minutes at 4°C.

Gel Electrophoresis and Transfer:

• Load 20-40 μg of total protein per lane on 10% SDS-PAGE gels.

• Include positive controls (cell lines known to express SPTLC1, such as K562 cells) .

• SPTLC1 runs at approximately 53 kDa.

• Transfer to PVDF membrane and block with 5% non-fat dry milk or BSA in TBST.

Antibody Incubation:

• Dilute primary SPTLC1 antibody according to manufacturer specifications (typically 0.04-0.4 μg/mL for Western blotting) .

• Commercial options include mouse monoclonal (sc-374143), which detects SPTLC1 protein from mouse, rat, and human origins , and various rabbit polyclonal antibodies (HPA010860, ab176706, ABS1642) .

• Incubate overnight at 4°C, followed by appropriate HRP-conjugated secondary antibody.

Detection Optimization:

• For quantification, consider using LI-COR Odyssey system with appropriate secondary antibodies.

• When analyzing phosphorylation status, Clean-Blot IP Detection Reagent (HRP) is recommended to minimize interference from immunoglobulin chains .

How do I validate the specificity of SPTLC1 antibodies in my experimental system?

Rigorous validation is essential for ensuring antibody specificity and reliable experimental outcomes:

Genetic Validation:

• Use SPTLC1 knockout or knockdown models as negative controls. Endothelial cell-specific SPTLC1 knockout (Sptlc1 ECKO) mice show approximately 80% reduction in SPTLC1 expression in endothelium .

• CRISPR-Cas9-mediated SPTLC1 knockout cell lines (e.g., HEK293 SPTLC1-KO) provide excellent negative controls .

Multiple Antibody Approach:

• Use antibodies from different sources that recognize distinct epitopes of SPTLC1:

  • Monoclonal antibodies targeting specific domains (sc-374143)

  • Polyclonal antibodies recognizing broader epitope ranges (HPA010860, targeting amino acids within central region)

  • Antibodies recognizing C-terminal regions (ab232847, targeting aa 100 to C-terminus)

Overexpression Controls:

• Transfect cells with FLAG-tagged SPTLC1 expression vectors and perform parallel detection with tag-specific antibodies .

Cross-Reactivity Assessment:

• Test for potential cross-reactivity with SPTLC2 and SPTLC3, which share structural similarities with SPTLC1.

What are the recommended fixation and permeabilization conditions for SPTLC1 immunofluorescence studies?

SPTLC1 is primarily an ER-localized protein with a transmembrane domain , requiring specific conditions for optimal detection:

Fixation Options:

• Paraformaldehyde fixation: 4% PFA in PBS (pH 7.4) for 15 minutes at room temperature.

• Alternative methods: 100% ice-cold methanol for 10 minutes at -20°C may better preserve membrane structure for this ER-resident protein.

Permeabilization Considerations:

• For PFA-fixed samples: 0.1-0.3% Triton X-100 in PBS for 5-10 minutes.

• For membrane protein preservation: 0.1% Saponin in PBS (less harsh) or 0.5% Digitonin (preferentially permeabilizes plasma membrane while preserving intracellular membranes).

Antibody Incubation:

• Block with 5% normal serum and 1% BSA in PBS.

• Dilute primary SPTLC1 antibodies typically 1:100 to 1:500.

• For co-localization studies with ER markers, consider markers such as calnexin or PDI to confirm proper localization .

What are the available conjugated forms of SPTLC1 antibodies and their applications?

A variety of conjugated SPTLC1 antibodies are available, each optimized for specific applications:

Available Conjugates Table:

Data sourced from commercial antibody specifications .

Application-Specific Considerations:

• For multiplexed imaging: Choose conjugates with well-separated emission spectra.

• For super-resolution microscopy: Alexa Fluor conjugates generally provide superior brightness and photostability.

• For flow cytometry: PE conjugates offer higher sensitivity than FITC conjugates.

How do I perform immunoprecipitation using SPTLC1 antibodies?

SPTLC1 immunoprecipitation requires optimization to preserve protein complexes and post-translational modifications:

Lysis Buffer Selection:

• For standard IP: RIPA buffer with protease inhibitors .

• For preserving protein complexes: Milder buffer with 1% digitonin, which better preserves membrane protein interactions .

Immunoprecipitation Protocol:

• Pre-clear lysate (1-2 mg/ml) with Protein G-Sepharose for 1 hour at 4°C.

• Add 2-5 μg of SPTLC1 antibody per mg of total protein. Include isotype control.

• Incubate overnight at 4°C with gentle rotation.

• Add Protein G-Sepharose beads and incubate for 3-4 hours at 4°C.

• Wash extensively with buffer containing reduced detergent concentration.

• Elute with SDS sample buffer or use non-denaturing elution for functional studies.

Analysis Considerations:

• For Western blot detection post-IP, use Clean-Blot IP Detection Reagent to minimize interference from immunoglobulin chains .

• For co-IP studies examining SPTLC1 interaction partners (SPTLC2, ORMDL proteins), digitonin-solubilized membrane fractions provide optimal results .

How do I distinguish between different SPTLC1 variants in my research models using available antibodies?

SPTLC1 variants associated with different diseases require specialized approaches for discrimination:

Variant Characteristics:

• ALS-associated variants (Y23F, L38R, L39del, F40S41del) cluster in the N-terminal transmembrane domain .

• HSAN1-associated variants (C133W, S331F) affect the catalytic domain .

• The exon 2 deletion variant (ex2del) shows distinct subcellular localization compared to wild-type SPTLC1 .

Experimental Approaches:

• Size discrimination by Western blot: The ex2del variant shows lower molecular weight due to the deletion .

• Epitope-specific antibodies: Select antibodies targeting regions that contain or flank the mutation sites.

• Subcellular localization: The ex2del variant is predominantly cytosolic rather than membrane-associated .

• Interaction partner analysis: ALS-associated variants show impaired binding to ORMDL proteins .

Variant Discrimination Table:

Information compiled from functional studies of SPTLC1 variants .

What are the considerations for studying SPTLC1 phosphorylation using phospho-specific antibodies?

SPTLC1 phosphorylation represents an important regulatory mechanism, particularly the ABL-mediated tyrosine phosphorylation at Tyr164:

Phospho-Antibody Approaches:

• For Tyr164 phosphorylation: Use phospho-tyrosine-specific antibodies recognizing the sequence context around Tyr164 .

• After SPTLC1 immunoprecipitation, probe with pan-phospho-tyrosine antibodies (e.g., 4G10).

Sample Preparation for Phosphorylation Preservation:

• Add phosphatase inhibitors to all buffers (sodium orthovanadate, sodium fluoride, β-glycerophosphate).

• Maintain samples at 4°C throughout processing.

• Consider direct lysis in hot SDS sample buffer for maximal phosphorylation preservation.

Experimental Design:

• Include appropriate positive controls: BCR-ABL-expressing cells show enhanced SPTLC1 phosphorylation .

• Include imatinib treatment as a negative control: "Inhibition of BCR-ABL using either imatinib or shRNA-mediated silencing led to the activation of SPTLC1" .

• Incorporate the Y164F SPTLC1 mutant as a non-phosphorylatable control: "Mutation of Tyr 164 to Phe in SPTLC1 increased serine palmitoyltransferase activity" .

Functional Correlation:

• Assess how phosphorylation status impacts SPT enzymatic activity.

• Analyze sphingolipid profiles using LC-MS/MS to determine how phosphorylation affects lipid metabolism.

• Evaluate impact on cellular phenotypes: "The Y164F mutation also promoted the remodeling of cellular sphingolipid content, thereby sensitizing K562 cells to apoptosis" .

How can I use SPTLC1 antibodies to investigate the interaction between SPTLC1 and ORMDL proteins?

The interaction between SPTLC1 and ORMDL proteins is critical for regulating SPT activity and is disrupted in ALS-associated SPTLC1 variants:

Co-Immunoprecipitation Approaches:

• Use mild detergent buffer with 1% digitonin for membrane protein preservation .

• "SPTLC1-ALS variants map to a transmembrane domain that interacts with ORMDL proteins, negative regulators of SPT activity" .

• Perform reverse IP (anti-ORMDL precipitating SPTLC1) to confirm specificity.

Optimized Protocol:

• Isolate membrane fractions before solubilization.

• Solubilize with digitonin (0.5-1%) to maintain membrane protein interactions.

• Immunoprecipitate with anti-SPTLC1 antibodies.

• Probe Western blots for co-precipitating ORMDL proteins.

Advanced Visualization Methods:

• Proximity Ligation Assay (PLA): Detect interactions with spatial resolution (<40 nm).

• FRET analysis: For real-time interaction studies in live cells.

• Co-localization analysis: Calculate Pearson's correlation coefficient between SPTLC1 and ORMDL staining.

Functional Validation:

• Measure SPT activity in the presence or absence of ORMDL proteins.

• "ORMDL binding to the holoenzyme complex is impaired in cells expressing pathogenic SPTLC1-ALS alleles, resulting in increased SL synthesis" .

• "SPTLC1-ALS variants caused an unregulated synthesis of sphingolipids that did not respond to increasing concentrations of ORMDL3" .

What are the strategies for using SPTLC1 antibodies in studying the impact of SPTLC1 mutations on sphingolipid metabolism?

Investigating the relationship between SPTLC1 mutations and sphingolipid metabolism requires integrating antibody-based techniques with lipidomic analyses:

Analytical Framework:

• Expression Analysis: Use Western blotting to quantify SPTLC1 variant expression levels.

• SPT Complex Assembly: Analyze interaction with other components (SPTLC2/SPTLC3, SPTSSA/SPTSSB, ORMDL) .

• Subcellular Localization: Perform immunofluorescence to detect potential mislocalization .

Sphingolipid Analysis Integration:

• SPT Enzyme Activity: Measure formation of 3-oxosphinganine from immunoprecipitated complexes.

• Comprehensive Sphingolipid Profiling: Perform LC-MS/MS analysis of various sphingolipid species .

• Metabolic Labeling: Use isotope-labeled precursors to track sphingolipid synthesis pathways .

Model Systems:

• Cell Culture: Express variants in SPTLC1 knockout backgrounds (e.g., "HEK293 SPTLC1-KO cells") .

• Mouse Models: Analyze tissue-specific knockout models (e.g., "Sptlc1 ECKO mice") .

• Patient Samples: Analyze plasma from individuals with SPTLC1 mutations .

Substrate Manipulation:

• Serine Supplementation: "Limiting L-serine availability in SPTLC1-ALS–expressing cells increased 1-deoxySL and shifted the SL profile from an ALS to an HSAN1-like signature" .

• Alternative Substrate Testing: Monitor production of 1-deoxysphingolipids when providing alanine or glycine.

How do I interpret changes in SPTLC1 protein levels in relation to sphingolipid metabolism in disease models?

Interpreting SPTLC1 alterations requires understanding complex regulatory mechanisms in sphingolipid metabolism:

Baseline Understanding:

• SPTLC1 forms a complex with catalytic subunits (SPTLC2 or SPTLC3) .

• SPT catalyzes the first and rate-limiting step in sphingolipid synthesis .

• Activity is regulated by substrate availability and protein-protein interactions .

Tissue-Specific Effects:

• Endothelial SPTLC1 deletion affects vascular development: "Sptlc1 ECKO mice exhibited delayed retinal vascular development" .

• Tissue-specific deletion impacts systemic sphingolipid levels: "EC actively provide SL metabolites to circulation postnatally" .

• Rapid changes occur after deletion: "Rapid reduction of plasma S1P levels observed as early as 1 week and maintained thereafter" .

Variant-Specific Interpretation:

• ALS Variants: Despite normal protein levels, show increased canonical sphingolipid synthesis due to impaired ORMDL regulation .

• HSAN1 Variants: Affect substrate specificity, producing toxic 1-deoxysphingolipids .

• Heterozygous vs. Homozygous Effects: "Heterozygous (Sptlc1∆E2/+) mice do not exhibit significant disruptions in sphingolipid homeostasis" .

Functional Biomarkers Table: